[1]
World Health Organization. Coronavirus disease 2019 (COVID-19). Situation Report – 29.
www.who.int/docs/default-source/coronaviruse/situation-reports/20200218-sitrep-29-covid-19.pdf(Accessed on Feb. 19, 2020).
[2]
Chowell, G.; Abdirizak, F.; Lee, S.; Lee, J.; Jung, E.; Nishiura, H.; Viboud, C. Transmission characteristics of MERS and SARS in the healthcare setting: a comparative study. BMC Med., 2015, 13, 210.
[http://dx.doi.org/10.1186/s12916-015-0450-0] [PMID: 26336062]
[http://dx.doi.org/10.1186/s12916-015-0450-0] [PMID: 26336062]
[3]
Meyer, J.R.; Dobias, D.T.; Weitz, J.S.; Barrick, J.E.; Quick, R.T.; Lenski, R.E. Repeatability and contingency in the evolution of a key innovation in phage lambda. Science, 2012, 335(6067), 428-432.
[http://dx.doi.org/10.1126/science.1214449] [PMID: 22282803]
[http://dx.doi.org/10.1126/science.1214449] [PMID: 22282803]
[4]
World Health Organization. Middle East respiratory syndrome coronavirus (MERS-CoV).
www.who.int/emergencies/mers-cov/en/(Accessed on Feb. 19, 2020).
[5]
Center for Disease Control. The 2009 H1N1 Pandemic: Summary Highlights, April 2009-April 2010.
www.cdc.gov/h1n1flu/cdcresponse.htm(Accessed on Feb. 19, 2020).
[6]
China Daily / Asia News Network. First antiviral drug approved to fight COVID-19.
https://newsinfo.inquirer.net/1229781/first-antiviral-drug-approved-to-fight-covid-19(Accessed on Feb. 19, 2020).
[7]
Pillaiyar, T.; Meenakshisundaram, S.; Manickam, M. Recent discovery and development of inhibitors targeting coronaviruses. Drug Discov. Today, 2020. Epub ahead of print
[http://dx.doi.org/10.1016/j.drudis.2020.01.015]
[http://dx.doi.org/10.1016/j.drudis.2020.01.015]
[8]
Galasiti, K.A.C.; Kim, Y.; Damalanka, V.C.; Rathnayake, A.D.; Fehr, A.R.; Mehzabeen, N.; Battaile, K.P.; Lovell, S.; Lushington, G.H.; Perlman, S.; Chang, K-O.; Groutas, W.C. Structure-guided design of potent and permeable inhibitors of MERS coronavirus 3CL protease that utilize a piperidine moiety as a novel design element. Eur. J. Med. Chem., 2018, 150, 334-346.
[http://dx.doi.org/10.1016/j.ejmech.2018.03.004] [PMID: 29544147 ]
[http://dx.doi.org/10.1016/j.ejmech.2018.03.004] [PMID: 29544147 ]
[9]
Agostini, M.L.; Pruijssers, A.J.; Chappell, J.D.; Gribble, J.; Lu, X.; Andres, E.L.; Bluemling, G.R.; Lockwood, M.A.; Sheahan, T.P.; Sims, A.C.; Natchus, M.G.; Saindane, M.; Kolykhalov, A.A.; Painter, G.R.; Baric, R.S.; Denison, M.R. Small-molecule antiviral β-d-N 4-hydroxycytidine inhibits a proofreading-intact Coronavirus with a high genetic barrier to resistance. J. Virol., 2019, 93(24), e01348-e19.
[http://dx.doi.org/10.1128/JVI.01348-19] [PMID: 31578288]
[http://dx.doi.org/10.1128/JVI.01348-19] [PMID: 31578288]
Related Journals
Current Computer-Aided Drug Design
Article Metrics
12